Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 7Rectal Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Turcot syndrome 1Testicular Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Seminoma 1Recurrence 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Neoadjuvant Therapy 1

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Neoadjuvant Therapy × Clear all
NCT06664411 2025-08-19

Pola-ZR2P in Previously Untreated DLBCL

Navy General Hospital, Beijing

Phase 2 Recruiting
80 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡